Literature DB >> 21093554

Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies.

Washington X de Paula1, Angelo M L Denadai, Marcelo M Santoro, Aline N G Braga, Robson A S Santos, Rubén D Sinisterra.   

Abstract

In this work, low soluble supramolecular complex between the losartan potassium (Los) and hydroxypropil-β-cyclodextrin (HPβCD) were characterized throughout phase-solubility, NMR techniques ((1)H and 2D-ROESY) and isothermal titration calorimetry (ITC) in order to attain physical-chemical knowledge of the system. In addition, the hypertensive effect of composition Los/HPβCD was evaluated aiming to obtain a more efficient oral pharmaceutical composition. ESI mass spectrometry and ITC blank experiment demonstrate the presence of Los clusters at 30 mM pure solution. Phase-solubility experiments showed a "Bs" type system, due to the formation of a less soluble complex than pure Los. NMR demonstrated the short distance interactions between the Los and the cyclodextrin, where several possibilities of interactions were observed. ITC data suggest an average 1:1 stoichiometry of Los and the cyclodextrin. The complex demonstrated efficiency in hypertension control, presenting antagonist action on the pressure effect of angiotensin II within 30 h, as compared to Los alone, 6h, indicating that inclusion of Los in HPβCD enhanced the extent and duration of its antagonistic action. In this work, a model of interaction between Los and HPβCD was proposed based on dissociation of self-assembled Los followed by complexation with HPβCD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21093554     DOI: 10.1016/j.ijpharm.2010.11.008

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies.

Authors:  Narcisa Marangoci; Mihai Mares; Mihaela Silion; Adrian Fifere; Cristian Varganici; Alina Nicolescu; Calin Deleanu; Adina Coroaba; Mariana Pinteala; Bogdan C Simionescu
Journal:  Results Pharma Sci       Date:  2011-08-01

2.  SERS determination of the antihypertensive drugs prazosin and losartan by using silver nanoparticles coated with β-cyclodextrin.

Authors:  Jiawei Wu; Hao Ma; Xiangfeng Bu; Chao Ma; Lin Zhu; Baoqin Hao; Bing Zhao; Yuan Tian
Journal:  Mikrochim Acta       Date:  2019-11-18       Impact factor: 5.833

3.  Molecular modeling-based inclusion mechanism and stability studies of doxycycline and hydroxypropyl-β-cyclodextrin complex for ophthalmic delivery.

Authors:  Haohao Zhang; Meiwan Chen; Zixin He; Zhouhua Wang; Meimei Zhang; Zhouyang He; Qian Wan; Dan Liang; Michael A Repka; Chuanbin Wu
Journal:  AAPS PharmSciTech       Date:  2012-11-17       Impact factor: 3.246

4.  Losartan Interactions with 2-Hydroxypropyl-β-CD.

Authors:  Vasiliki Palli; Georgios Leonis; Nikoletta Zoupanou; Nikitas Georgiou; Maria Chountoulesi; Nikolaos Naziris; Demeter Tzeli; Costas Demetzos; Georgia Valsami; Konstantinos D Marousis; Georgios A Spyroulias; Thomas Mavromoustakos
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

Review 5.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.